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Abstract
We have designed, synthesized and tested conjugates of chemically modified luciferase siRNA
(Luc-siRNA) with bi-, tri- and tetravalent cyclic(arginine-glycine-aspartic) peptides (cRGD) that
selectively bind to the αvβ3 integrin. The cellular uptake, subcellular distribution and
pharmacological effects of the cRGD conjugated Luc-siRNAs as compared to un-conjugated
controls were examined using a luciferase reporter cassette stably transfected into αvβ3 positive
M21+ human melanoma cells. The M21+ cells exhibited receptor-mediated uptake of cRGD-
siRNA conjugates but not of unconjugated control siRNA. The fluorophore-tagged cRGD-siRNA
conjugates were taken up by a caveolar endocytotic route and primarily accumulated in cytosolic
vesicles. The bi-, tri- and tetravalent cRGD conjugates were taken up by M21+ cells to
approximately the same degree. However, there were notable differences in their pharmacological
effectiveness. The tri- and tetravalent versions produced progressive, dose-dependent reductions in
luciferase expression, while the bivalent version had little effect. The basis for this divergence of
uptake and effect is currently unclear. Nonetheless the high selectivity and substantial ‘knock
down’ effects of the multivalent cRGD-siRNA conjugates suggest that this targeting and delivery
strategy deserves further exploration.
INTRODUCTION
Antisense and siRNA oligonucleotides have displayed considerable promise for treatment of
a variety of diseases. Advancement of new chemistries and design features have led to
oligonucleotides that provide improved stability against nucleases, enhanced potency,
reduced immune responses and reduced toxicity profiles compared to early generations of
oligonucleotides.1–3 Excellent results for both antisense and siRNA have been attained in
cell culture and animal models, and this has driven the initiation of multiple clinical trials.1,4
However, despite important progress, a key impediment to the wider success of this
approach is poor delivery of oligonucleotides to their sites of action within cells, due to the
need to cross several biological barriers subsequent to administration.5,6
The endogenous regulatory mechanisms involved in RNA interference (RNAi) can be
activated by the delivery of short double stranded RNAs (siRNA) to the cell interior.7 The
mechanism of targeted mRNA degradation by siRNA is highly complex and not completely
understood. It includes the formation of an RNA-induced silencing complex (RISC) that
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contains the Argonaute 2 protein, while the Dicer RNase and other accessory proteins are
also important in loading of siRNA on to the RISC complex.8 The potency and specificity of
siRNAs can be improved and their impact on the innate immune system can be reduced via
chemical modification guided by design algorithms.3 Nonetheless, effective delivery of
siRNA to its intracellular sites of action remains a challenge.
One important modality for delivery of both antisense and siRNA molecules has been the
use of polymeric or lipid nanocarriers.9 Lipid based carriers have proven to be particularly
efficacious in the delivery of siRNA to the liver.10 A variety of polymeric11 or other types of
nanoparticles12 have also been employed for siRNA delivery. Effective deployment of
siRNA to tumors has been challenging, but recently targeted lipid based nanoparticles have
displayed substantial activity.13
An alternative approach for delivery of antisense and siRNA moieties involves covalent
conjugation of high affinity and receptor specific ligands that bind to cell surface
receptors.14–17 This strategy can be used to provide cell-type selective targeting and
delivery, and thereby to enhance tissue specific intracellular accumulation of
oligonucleotides. For example, we have utilized peptide ligands with high affinity to
integrins,18,19 to a G Protein-Coupled Receptor,20 or to the sigma receptor,21 to enhance
antisense oligonucleotide delivery into tumour cells that over-express these receptors.
In the present report we extend the strategy for tissue specific delivery of siRNAs by
conjugating high affinity cRGD ligands that are known to bind to αvβ3 integrin to luciferase
siRNA. The high affinity bi-, tri-, and tetravalent cRGD were conjugated to the 3′-end of the
sense strand of the siRNA. We demonstrate enhanced receptor-specific cellular uptake of
cRGD-siRNA conjugates and dose dependent inhibition of a luciferase reporter gene in the
absence of transfection agents. We also demonstrate uptake inhibition of cRGD-siRNA
conjugates by preincubation of the αvβ3 integrin positive cells22 with excess RGD peptide,




Bivalent, trivalent and tetravalent of cyclic RGD (cRGD) peptides were obtained from
Peptides International (Louisville, Kentucky). The amino acid residues of the bi-, tri- and
tetravalent cRGD peptides respectively are: H-Cys-Aca-Glu-[cyclo(Arg-Gly-Asp-D-Phe-
Lys)]2, H-Cys-Aca-Glu-[cyclo(Arg-Gly-Asp-D-Phe-Lys)]-Glu [cyclo(Arg-Gly-Asp-D-Phe-
Lys)]2 and H- Cys-Aca-Glu-{Glu-[cyclo(Arg-Gly-Asp-D-Phe-Lys)]2}2. A thiol group was
introduced to the cRGDs by attaching a cysteine residue via the spacer – 6-aminocaproic
acid, to the α-amino group of glutamic acid to enable conjugation of the peptide to a
maleimide containing oligonucleotide under Michael addition conditions (Figure 1).
Solid-Phase Synthesis of Modified siRNA Targeting the Firefly Luciferase Gene
All oligonucleotides used in this study were synthesized on an ABI 394 DNA synthesizer
using standard phosphoramidite chemistry with commercially available phosphoramidite
monomers. The oligonucleotides were de-protected with methylamine solution at 65 °C for
10 min (40 wt % in water) followed by DMSO wash and cooled on dry ice for 10 min, then
treated with TEA.3HF at 65 °C for 12 min. All oligonucleotides were purified by anion-
exchange HPLC and characterized by LC-MS analysis. For peptide conjugation an amino
linker was introduced at the 3′-end of the sense strand by initiating the oligonucleotide
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synthesis on a trans-4-hydroxyproline based support 4 under standard oligonucleotide
synthesis conditions (Scheme 1).
Postsynthetic Conjugation of cRGD Peptides to Oligonucleotide
The HPLC purified amino linked sense strand 5 (23.6mg, 3.35μmole) was reacted with 6-
maleimidohexanoic acid N-hydroxysuccinimide ester (EMCS) (21mg, 68μmol) in 1x PBS
buffer, at pH 7.2 for 20min at RT to obtain maleimido modified sense strand 6 (Scheme 1).
The reaction mixture was then diluted with HPLC grade water (15mL) and directly loaded
onto a Waters XTerra RP-18 column on an AKTA purifier (GE Healthcare, USA) and
purified using a gradient of buffers A and B. Buffer A: 0.1M TEAA at pH 7.0 and buffer B:
CH3CN; gradient: 0% B for 1 column volume, then 10% to 50% of B for 5 column volumes
and 50% to 100% of B for 2 column volumes; flow rate:15mL/min, UV: 260nm. The HPLC
fractions with the right mass were collected (22.6mg, 3.11μmol, 93%), aliquoted into the
desired quantity and treated immediately with peptides 1–3 individually to obtain the desired
cRGD conjugated sense strands 7–9 (Scheme 1). The products formed were analyzed by
analytical HPLC and LC-MS to confirm integrity.
Bivalent cRGD peptide 1 (1.6mg, 1.02μmol) was dissolved in water (1mL) and added to the
solution of maleimido oligonucleotide 6 (3mg, 0.41μmol) in 0.4M KCl with 40% CH3CN,
and the mixture was incubated overnight at room temperature. The reaction mixture was
dialyzed in water and loaded onto a Waters XTerra RP-18 column on the AKTA purifier and
purified using buffers A and B under same conditions used for the purification of maleimido
oligonucleotide 6. Fractions containing the bivalent conjugate 7 were pooled and lyophilized
(3.4mg, 0.39μmol, 95%). The tri- and tetravalent cRGDs (2 and 3) were conjugated to
maleimido oligonucleotide 6 under similar conditions to obtain the corresponding
oligonucleotide conjugates 8 and 9 (Scheme 1). Post-synthetic conjugation of trivalent
cRGD peptide 3 (2.3mg, 1.02μmol) to maleimido oligonucleotide 6 (3mg, 0.41μmol)
yielded the conjugate 8 (3.3mg, 0.348μmol, 84%). Conjugation of the peptide 3 (2.0mg,
0.68μmol) to oligonucleotide 6 (2mg, 0.27μmol) gave the desired conjugate 9 (1.8mg,
0.18μmol, 67%). The trivalent cRGD conjugated sense strand 10 (Table 1) of a more potent
luciferase siRNA was also synthesized according to similar conditions. All conjugated
oligonucleotides were analyzed by HPLC and LC-MS to confirm the integrity of the
products formed (Table 1).
Similarly antisense strand 15 with the fluorophore Alexa 488 at the 3′-end was obtained
from the corresponding amino linked antisense strand synthesized from the solid support 4
(Scheme 1). The amino linked oligonucleotide obtained from 4 was post-synthetically
reacted with commercially available Alexa 488 NHS ester to obtain the fluorophore tagged
antisense strand 15 under similar conditions described for the synthesis of maleimido
oligonucleotide 6.
Preparation of Luciferase cRGD-siRNA Conjugates
cRGD-siRNA conjugates with and without the fluorophore Alexa 488 were prepared for the
present study. Annealing of cRGD conjugated oligonucleotides 7–9 individually with
equimolar amount of antisense strand at 95 °C for 3 min in sterile water followed by slow
cooling afforded the siRNAs 11, 12 and 13 (Scheme 1, Table 2). While our studies were in
progress we identified a more potent luciferase siRNA sequence and a trivalent cRGD-
siRNA conjugate 14 of the potent siRNA was also prepared to study conjugate mediated
RNAi activity in vitro. Similarly annealing of conjugates 7–9 with Alexa 488 tagged
antisense strand 15 afforded the fluorophore labeled siRNAs 16–18 (Scheme 1, Table 2).
Each set contains the control siRNAs 19 and 20 with no cRGD moiety. Duplex formation
was confirmed by capillary gel electrophoresis and LC-MS analysis.
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M21+ melanoma cells with high expression of αvβ3 integrin,22 as well as M21- cells that
lack this integrin, were obtained from Dr. D. Cheresh (University of California, San Diego)
and were cultured in DMEM medium (Gibco/Invitrogen) supplemented with 10% FBS
(Sigma). M21+ cells were transfected with a luciferase expression plasmid pGL3-promoter
(Promega) and pcDNA3.1/hygro (Invitrogen) at a 10:1 ratio using an Amaxa
Nucleoporation system as per manufacturer’s instructions. Selection was carried out in
DMEM medium containing 500 μg/ml hygromycin B (Roche) and 10% FBS for two weeks.
Individual clones were picked and screened for luciferase activity using a Luciferase assay
kit (Promega). The single cell clone with the highest activity was referred to as M21+GL3
and used in further studies.
Cell uptake studies
Uptake studies of the fluorescently labeled siRNA conjugates were performed similarly to
our previous studies on uptake of antisense oligonucleotides.20 Briefly, total cellular uptake
of the Alexa 488-labeled siRNA was measured by flow cytometry using a LSR II cell
analyzer (Becton-Dickenson, San Jose, CA, USA). After treatment with oligonucleotides for
various times, the cells were trypsinized and analyzed by flow cytometry, with a 490 nm
laser and 520 nm emission filters for Alexa 488 fluorescence. In all cases oligonucleotide
concentrations used were normalized on Alexa 488 fluorescence.
Luciferase knockdown studies
M21+GL3 cells were treated with various concentrations of cRGD- conjugated or control
siRNAs for 4 h. in serum free medium. At this point serum was added to 2% and the
incubation continued to 96 h. Cells were lysed and luciferase activity and cell protein
determined as previously described.20
Confocal fluorescence microscopy
Intracellular distribution of the Alexa 488 labeled siRNA conjugates in living cells was
examined using an Olympus Confocal FV300 fluorescent microscope with 63×-oil
immersion objectives. M21+GL3 cells were plated in 35 mm glass bottom microwell dishes
(MatTek, Ashland, MA). Intracellular uptake of the siRNA conjugates (50 nM) was
visualized by confocal microscopy after 4-hour or 24-hour treatment. Co-localization of the
RGD-siRNA-Alexa 488 conjugates with Alexa 594 labeled transferrin (Tfn) or cholera toxin
B (CTB) (Invitrogen), as markers for clathrin-coated vesicles and lipid rafts, respectively,
was also done by confocal microscopy. Transferrin (20 μg/ml) and cholera toxin B (4μg/ml)
were used for 15 minutes and 30 minutes, respectively, prior to live cell imaging.
RESULTS
Synthesis and characterization
The chemical structure of the trivalent cRGD peptide is illustrated in Figure 1; the bi- and
tetravalent versions have analogous structures. Each peptide contains a cysteine residue
attached to the 6-aminohexanoic acid that joins the cRGD moieties through the glutamic
acid residue. The thiol (−SH) reactive group of the cysteine residue of each peptide
undergoes chemical conjugation to the maleimide functionality of the sense strand of firefly
luciferase siRNA via a Michael addition reaction. The amino linked sense strand 5 of
luciferase RNA obtained from the solid support 4 as shown in Scheme 1 was reacted with 6-
maleimidohexanoic acid N-hydroxysuccinimide ester to obtain maleimido functionalized
sense strand 6. The reaction was performed under controlled conditions for only 20 min in
1x PBS buffer at pH 7.2 to avoid maleimide degradation. The product was immediately
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purified by RP-HPLC and the purified material was directly used for the conjugation
reaction. The peptide conjugation reaction occurred between the maleimido functionalized
sense strand 6 of luciferase siRNA and the reactive thiol group (−SH) of the multivalent
cRGD peptides 1–3 (Scheme 1). Using 2.5 equivalents of peptide in each conjugation
reaction, almost all starting maleimido oligonucleotide 6 was consumed and converted to the
corresponding cRGD conjugated sense strand with an excellent yield (Table 1). The
conjugates were purified by reverse-phase HPLC (RP-HPLC) using an AKTA purifier. The
HPLC profiles for the purification of bivalent, trivalent and tetravalent cRGD conjugates are
shown in Figure 2 (a), (b) and (c) respectively. The arrows in each RP-HPLC chart indicate
the position of maleimido oligonucleotide 6 and the corresponding cRGD conjugate. Each
HPLC profile showed that the conjugate peak was clearly resolved from its precursor 6.
After purification, bivalent cRGD conjugate 7 was obtained at relatively higher yield (95%)
than trivalent cRGD conjugate 8 (84%) which in turn was higher than the tetravalent
conjugate 9 (67%). After lyophilization, the conjugates were re-dissolved in sterile water
without any difficulty. We have not seen aggregation of these conjugates in water. For all
cases, the structure of the final product was confirmed by LC-MS analysis.
Annealing of siRNA-cRGD Conjugates
After conjugation of cRGD peptides to the 3′-end of the sense strand of luciferase siRNA,
we initially attempted to anneal the cRGD conjugated sense strand 7–9 with the
complementary antisense strand in 1x PBS buffer at pH 7.4 according to a standard
annealing procedure.23 However we observed a degradation of the cRGD conjugated sense
strand during annealing process with the extent of degradation depends on annealing
temperature. The degraded products were identified as the corresponding cRGD peptide and
the carboxylic acid 19 by LC-MS analysis. The plausible mechanism of degradation of the
cRGD-siRNA conjugate at elevated temperature in PBS buffer at pH 7.4 is the intra-
molecular amine assisted retro-Michael addition reaction shown in Scheme 2. Interestingly
the degradation was not observed in metal free sterile water at elevated temperature.
Therefore, the annealing was performed in sterile water to obtain the desired cRGD-siRNA
conjugates 11–14 and 16–18 (Scheme 1). We prepared two sets of cRGD-siRNA conjugates
in sterile water with fluorescently labeled antisense strand 15 or one without the fluorescent
label (Table 2). The appendage of the reporter group to the antisense strand of cRGD-siRNA
conjugates 16–18 enabled evaluation of cRGD assisted cellular uptake and intracellular
trafficking of the conjugates. The conjugates 11–14 with no fluorescent tag were used for
the determination of the efficacy of the conjugates by knockdown assay. After annealing, the
integrity of double stranded cRGD-siRNA conjugates were analyzed and confirmed by
capillary gel electrophoresis and LC-MS analysis.
Cellular uptake
The conjugation of cRGD moieties dramatically enhanced the uptake of siRNA by
M21+GL3 melanoma cells. As seen in Figure 3, the control non-conjugated siRNA 20
displayed little uptake at all concentrations tested. In contrast, the bi-, tri-, and tetravalent
cRGD conjugates 16–18 each displayed enhanced uptake that increased progressively with
concentrations ranging from 5 to 100 nM. No evidence of saturation of uptake was noted in
the concentration range tested. Previous studies have indicated that the affinities of
multivalent RGD conjugates for αvβ3 are in the range of 30–100nM.24 However, we did not
seek to measure affinity in the current study. There were no major differences in the uptake
of the siRNA with bi, tri or tetravalent conjugation. The uptake of the cRGD-siRNA
conjugates clearly involved specific interactions of the RGD group with its receptor, since
αvβ3 positive M21+ cells accumulated far more of the RGD-conjugated siRNA than the
control non-conjugated siRNA while αvβ3 negative M21- cells did not (Figure 4A).
Further, excess RGD peptide competitively blocked the cRGD-siRNA uptake process
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(Figure 4B). In contrast, uptake was only slightly affected by the presence of serum proteins
even though some potential competitors such as vitronectin and fibronectin are present in
low amounts in serum (Figure 4C). Uptake and RGD inhibition experiments were also
conducted with compound 14, a trivalent conjugate with a more potent siRNA sequence.
The results were similar to the other RGD conjugates and are shown in the Supplementary
Material (Figure S1).
Inhibition of luciferase expression
The cRGD conjugates 11–13, as well as the control non-conjugated siRNA 19 were
designed to inhibit luciferase expression. The control siRNA 19 had no activity unless it was
complexed with a transfection agent. For example, when complexed with Lipofectamine
2000, the non-conjugated control at 100 nM caused approximately an 80% reduction in
luciferase activity. The cRGD conjugated siRNAs were tested in the absence of any
transfection agent. Interestingly the tri- and tetravalent cRGD conjugates 12 and 13
produced progressive dose-dependent reductions in luciferase activity while the bivalent
version 11 had little effect (Figure 5). Using the original siRNA sequence, the trivalent
cRGD conjugate 12 produced a 40% reduction in luciferase at 50nM. During the course of
our studies we identified a more potent luciferase siRNA for cRGD conjugation and it was
conjugated to the trivalent cRGD ligand to obtain the conjugate 14 (Table 2). The newly
designed conjugate 14 produced a 70% reduction in luciferase at 25 nM (Figure 5).
Interestingly the biological effect of luciferase knockdown was not well correlated with the
total cell uptake. As shown in Figure 3, all three fluorophore labeled cRGD conjugates 16–
18 displayed enhanced cell uptake, but as seen in Figure 5 only the tri- and tetravalent
versions produced significant knockdown.
Subcellular localization
We examined the subcellular localization of the Alexa 488 labeled siRNA at 4 and 24 h time
points, comparing the unconjugated 20 and tetravalent cRGD conjugate 18. As seen in
Figure 6A, the unconjugated labeled siRNA 20 was not detectable, while the cRGD
conjugate 18 displayed substantial uptake into vesicular structures in the cytosol, these
presumably being various types of endosomes. At 24 h the accumulated fluorescence was
more intense and was now concentrated in perinuclear locations. Most of the material
continued to be vesicular, although some slight cytosolic fluorescence was discernable. In
order to more precisely identify the endomembrane compartments involved in the uptake
and trafficking of the RGD-siRNA, we co-incubated the Alexa 488 labeled oligonucleotide
(green) with Alexa 594 (red) labeled markers for well-known endocytotic pathways. Thus
transferrin is known to be internalized via the clathrin coated pit pathway, while cholera
toxin is substantially internalized via the caveolar pathway or other lipid raft dependent
pathways.25 As seen in Figure 6B, at 4 h there was virtually no overlap of the labels for
transferrin and siRNA; in contrast there was substantial overlap of the cholera toxin and the
cRGD siRNA conjugate 18. This suggests that the initial uptake pathway for cRGD-siRNA
involves calveolae; this observation is consistent with literature on the mechanism of
internalization of the αvβ3 integrin.26 We further investigated the uptake pathways by using
a series of well-known pharmacological inhibitors of various endocytotic processes. The
trivalent cRGD-siRNA 14 was incubated with M21+ cells in the presence of non-toxic
concentration of selected inhibitors and the results are summarized in Table 3. Methyl-β-
cyclodextrin, an agent that affects lipid raft stability, had the greatest inhibitory effect. This
observation supports the notion that lipid raft/caveolar pathways are important in the
internalization of the RGD-conjugates.
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There was little toxicity associated with the use of the cRGD-siRNA conjugates at the
concentrations examined. Thus in the ‘knockdown’ experiments of Figure 5 the cell protein
recovered in each of the treated samples was essentially the same as for the untreated
control. The only exceptions were the cases where Lipofectamine 2000 was used where
some protein loss was observed (data not shown). Additionally the cells treated with the
cRGD-siRNA conjugates maintained normal morphology as illustrated in the DIC images of
Figure 6.
DISCUSSION
It would be of substantial value to be able to effectively target antisense or siRNA
oligonucleotides to specific cell types by making use of differential expression of cell
surface receptors. In this study we have focused on the αvβ3 integrin, a cell surface
glycoprotein that is preferentially expressed in angiogenic endothelia and in certain tumor
types including melanomas.27,28 The process of targeted oligonucleotide delivery using
conjugates with high affinity ligands involves several steps. First there is selective
association with the receptor followed by some form of endocytosis of the receptor-ligand
complex. This is followed by trafficking through various endomembrane compartments such
as early and late endosomes, the trans-Golgi apparatus, and lysosomes. Finally, there is
release from membrane bound compartments into the cytosolic or nuclear sites of action,
respectively, of siRNA and antisense oligonucleotides.5 It has become clear that there are
important relationships between the intracellular trafficking of receptors and their functional
activity.29 Likewise we have developed initial evidence that intracellular trafficking
pathways can influence the pharmacological activity of oligonucleotides.19
The current report demonstrates that high affinity cRGD ligands can strongly and
specifically enhance uptake of siRNA by cells that express the αvβ3 integrin. Uptake was
blocked by excess unconjugated RGD peptide and receptor positive M21+ cells accumulated
the cRGD-siRNA conjugates to a much greater degree than receptor negative M21- cells.
Interestingly, increasing the valency from bi- to tetravalent had little effect on the magnitude
of the overall uptake process. Confocal microscopy and inhibitor studies indicated that
initial uptake of the cRGD-siRNA conjugates was primarily via caveolar endocytosis.
A surprising result was the difference in pharmacological effectiveness of conjugates with
differing valencies. While the bivalent cRGD-siRNA conjugate displayed only a slight
effect, the tri- and tetravalent versions produced substantial dose-dependent reduction in
luciferase expression. This was especially true of the trivalent conjugate 14 made with the
more potent luciferase siRNA sequence. Since all of the conjugates were taken up
approximately equally well, this suggests that events downstream of the initial uptake are
responsible for the different effects observed. One possibility is that the several conjugates
follow different intracellular trafficking pathways or traverse those pathways at different
rates. However, our current observations indicate that, at least at early time points, the
tetravalent cRGD-siRNA conjugate follows the caveolar internalization pathway that we
have previously described for bivalent cRGD-oligonucleotide conjugates.18 It is possible
that the higher valency conjugates are retained more effectively within the cells at later time
points, but this issue is difficult to study because of the inevitable degradation of the siRNA
at longer times. Another possibility is that the presence of multiple cRGD peptides may
cause a destabilization of the endosome membrane leading to more effective oligonucleotide
release to the cytosol. However, at this point we do not have a clear-cut mechanistic
explanation of the differing efficacy of the bi- and multivalent conjugates. Nonetheless the
current results are encouraging in that they clearly demonstrate receptor specific targeting
and significant pharmacological effects of multivalent ligand-siRNA conjugates. This could
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emerge as an interesting alternative to the delivery of siRNA using various forms of lipid or
polymer nanoparticles. However, further evolution of the chemical conjugation approach
will require both a better understanding of mechanism and also validation in an in vivo
setting.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. Chemical structure of cysteine-bearing cyclic RGD (cRGD) peptide
The cysteine is connected to a 6-aminohexanoic acid linker that joins two, three and four
cyclic RGD moieties respectively for the bi-, tri and tetravalent versions. Only the trivalent
peptide is shown here. Arrow indicates the site of conjugation of the peptide (thiol) to the
maleimide functionality on the luciferase siRNA sense strand.
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FIGURE 2. The conjugation of multivalent cyclic RGD peptides to the maleimide containing
sense strand of the luciferase siRNA
The oligonucleotides (A-59841.1 and A-59842.1) were purified by HPLC after each step in
the synthesis.
(I) 6-Maleimidohexanoic acid N-hydroxysuccinimide ester, 1x PBS buffer, pH 7.2, 20 min,
room temperature (RT);
(II) Cysteine-bearing multivalent cRGD peptides, 0.4M potassium chloride, 40% aqueous
acetonitrile, overnight, RT.
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FIGURE 3. HPLC Analysis
AKTA RP-HPLC purification profiles for the crude reaction mixtures of (a) bivalent (b)
trivalent and (c) tetravalent RGD-sense oligonucleotide conjugates. Arrows indicate the
relative change of retention time of the conjugates (A-69252.1, A-69253.1, and A-69254.1)
from the maleimide-RNA sense strand (A-59842.1). HPLC analysis was performed as
described in the materials and methods section.
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FIGURE 4. Possible degradation product
A possible mechanism for the degradation of cRGD-sense strand conjugate in 1X PBS
buffer, pH 7.4 during annealing (95°C, 3min, then cooled to RT).
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FIGURE 5. Uptake dose-response for control and cRGD- conjugated siRNAs
M21+GL3 cells were treated with various concentrations of control or RGD-conjugated
Alexa 488 labeled siRNA for 4 h at 37°C in OPTI-MEM without serum. Thereafter the cells
were harvested and analyzed for fluorescence levels by flow cytometry. Results are the
means and standard errors of triplicate determinations.
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FIGURE 6. (A) Uptake of cRGD-conjugated siRNA by M21+ or M21- cells
M21+GL3 cells (avb3 positive) or M21- cells (avb3 negative) were treated with 100 nM
control or tetravalent RGD conjugated siRNA for 4 h. Uptake of Alexa 488 labeled siRNA
was measured by flow cytometry. Data normalized on M21+ cells with RGD-siRNA as
100%. (B) Uptake of tetravalent RGD-siRNA conjugates plus or minus the presence of
cycloRGD inhibitor. M21+GL3 cells were pretreated with 10 mg cycloRGD peptide for 15
min followed by treatment with 50 nM control siRNA or tetravalent cRGD-siRNA for 4 h at
37°C. Thereafter the cells were harvested and analyzed for Alexa 488 fluorescence levels by
flow cytometry. Data normalized on RGD-siRNA (no inhibitor) as 100%. (C) Uptake of
RGD-conjugated siRNA with or without serum. M21+GL3 cells were treated with 100 nM
control or RGD conjugated siRNAs for 4 h at 37°C in OPTI-MEM with 5% FBS or without
serum. Thereafter the cells were harvested and analyzed for fluorescence levels by flow
cytometry. Data normalized on tetra-RGD-siRNA (no serum) as 100%. Results A–C are
means and standard errors of triplicate or quadruplicate determinations.
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FIGURE 7. Knockdown dose-response for cRGD conjugated siRNAs
M21+GL3 cells were treated with various concentrations of control siRNA or RGD-
conjugated siRNA for 4 h at 37°C in OPTI-MEM without serum. The control siRNA
complexed with Lipofectamine 2000 was used as a positive control. After 4 h serum was
added to 2% to all wells with the exception of the Lipofectamine 2000 in which the medium
was replaced with DMEM-H with 2% serum. After 96 h the cells were lysed and
luminescence analyzed on a Fluostar Omega microplate reader and normalized to total
cellular protein. Results are the means of pentuplicate determinations and are expressed as
percent of untreated control cells (ordinate). The abcissa shows siRNA concentrations (nM).
The unconjugated siRNA had no effect at any concentration tested (not shown) unless it was
complexed with Lipofectamine 2000, in which case an 80% reduction was attained at 100
nM for the original sequence while a 99% reduction was obtained for the ‘B’ sequence (not
shown).
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FIGURE 8. (A) Cellular distribution of siRNAs
M21+GL3 cells were incubated with control siRNA-Alexa 488 (50 nM) for 4 hours or
Tetravalent RGD-siRNA-Alexa 488 (50 nM) for 4 hours and 24 hours. Live cells were
observed by confocal fluorescence microscopy as described in the materials and methods
section. B. Co-localization with endocytosis markers. Tetravalent RGD-siRNA-Alexa 488
(50 nM) was co-incubated with Alexa-594 labeled transferrin (Tfn) (20 μg/ml) and cholera
toxin B (CTB) (4 μg/ml). Live cells were observed by confocal fluorescence microscopy as
above. Selected vesicles showing co-localization are marked with white arrows.
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Conjugation of cRGD peptides to siRNA
a (i) Solid phase oligonucleotide synthesis and deprotection; (ii) PBS buffer, pH 7.2, rt, 20
min;(iii) 0.4M KCl, 40% MeCN in H2O, rt, overnight; (iv) antisense strand, annealing at 95
°C in H2O;(v) Alexa 488 NHS ester, PBS buffer, pH 7.2, 20 min.
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a Intra-molecular amine assisted retro Michael addition of cRGD-Oligonucleotide conjugate
at elevated temperature (>90 °C) in PBS buffer at pH 7.4.
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Table 2
Luciferase siRNAs conjugated to multivalent cRGD
siRNA S/ASa Sequence (5′-3′)b cRGD content
19 S cuuuAcGcuGAGuAcuucGAdTdT 0
AS UCGAAGuACUcAGCGuAAGdTdT
11 S cuuuAcGcuGAGuAcuucGAdTdTX1 2
AS UCGAAGuACUcAGCGuAAGdTdT
12 S cuuuAcGcuGAGuAcuucGAdTdTX2 3
AS UCGAAGuACUcAGCGuAAGdTdT
13 S cuuuAcGcuGAGuAcuucGAdTdT X3 4
AS UCGAAGuACUcAGCGuAAGdTdT
14 S AccGAAAGGucuuAccGGAdTsdTX2 3
AS UCCGGuAAGACCUUUCGGUdTsdT
20 S cuuuAcGcuGAGuAcuucGAdTdT 0
AS UCGAAGuACUcAGCGuAAGdTdTY
16 S cuuuAcGcuGAGuAcuucGAdTdT X1 2
AS UCGAAGuACUcAGCGuAAGdTdTY
17 S cuuuAcGcuGAGuAcuucGAdTdT X2 3
AS UCGAAGuACUcAGCGuAAGdTdTY
18 S cuuuAcGcuGAGuAcuucGAdTdTX3 4
AS UCGAAGuACUcAGCGuAAGdTdTY
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Table 3
Effects of Inhibitors on cRGD-siRNA Uptake
siRNA 50 nM Drug/Inhibitor Conc. Endocytosis Pathway Putatively Affected cRGD-siRNA uptake
14 None 100 ± 1.4 %
Chlorpromazine 2.5 μM Clathrin mediated endocytosis 93.3 ± 1.9 %
Methyl-β-cyclodextrin 1 mM Lipid-raft mediated endocytosis 42.8 ± 1.0 %
Amiloride 100 μM Macropinocytosis 98.5 ± 2.3 %
Cytochalasin D 2 μM Actin inhibitor 37.9 ± 0.9 %
M21+ cells were treated with the indicated non-toxic concentration of drugs and trivalent cRGD-siRNA 14. Uptake was measured after 3 h by flow
cytometry. Results were normalized to uptake of the siRNA conjugate 14 by the drug/inhibitor free control cell lines.
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